» Articles » PMID: 35905469

The Longitudinal Relation of Inflammation to Incidence of Vasomotor Symptoms

Overview
Journal Menopause
Date 2022 Jul 29
PMID 35905469
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Vasomotor symptoms (VMS), the most frequently reported symptoms during the menopausal transition, have been associated with inflammation. Whether inflammation is a risk factor for or a consequence of VMS remains unclear. The objectives of these analyses were to determine if elevated proinflammatory marker levels were associated with increased incident VMS in women without VMS at baseline and whether these associations varied by menopause transition stage or race/ethnicity.

Methods: We used longitudinal data on incident VMS, high-sensitivity C-reactive protein (hs-CRP; n = 1,922) and interleukin-6 (IL-6; n = 203) from 13 follow-up visits in the Study of Women's Health Across the Nation, which included five racial/ethnic groups of midlife women. We performed multivariable discrete-time survival analyses to determine adjusted hazard ratios (aHRs) for the association of these proinflammatory markers with incident VMS in women without VMS at baseline.

Results: We found no significant associations of incident VMS with dichotomized hs-CRP (>3 vs ≤3 mg/L) at baseline, concurrent or prior visit (aHRs, 1.04-2.03) or IL-6 (>1.44 vs ≤1.44 pg/mL) at visit 1, concurrent or prior visit (aHRs, 0.67-1.62), or continuous hs-CRP or IL-6 values over 13 follow-up visits (with nonsignificant adjusted increased hazards ranging from 0% to 2%).

Conclusions: Our results showed no significant association of the proinflammatory biomarkers, hs-CRP or IL-6, either concurrently or with subsequent incident VMS, indicating that inflammation was unlikely to be a risk factor for VMS. Thus, clinical treatments directed at reducing inflammation would be unlikely to reduce the occurrence of VMS.

Citing Articles

A Systematic Review of Anxiety and Depressive Symptoms Among Women Experiencing Vasomotor Symptoms Across Reproductive Stages in the US.

Gibson C, Ajmera M, OSullivan F, Shiozawa A, Lozano-Ortega G, Badillo E Int J Womens Health. 2025; 17:537-552.

PMID: 40034973 PMC: 11874770. DOI: 10.2147/IJWH.S491640.


Considering the role of estradiol in the psychoneuroimmunology of perimenopausal depression.

Bondy E Brain Behav Immun Health. 2024; 40:100830.

PMID: 39161877 PMC: 11331712. DOI: 10.1016/j.bbih.2024.100830.


Prospective early adulthood risk factors for vasomotor symptoms in the Coronary Artery Risk Development in Young Adults study.

Kim C, Lane A, Vu T, Lewis C, Yin Z, Jiang H Menopause. 2024; 31(2):108-115.

PMID: 38270902 PMC: 10827353. DOI: 10.1097/GME.0000000000002306.

References
1.
Waetjen L, Johnson W, Xing G, Feng W, Greendale G, Gold E . Serum estradiol levels are not associated with urinary incontinence in midlife women transitioning through menopause. Menopause. 2011; 18(12):1283-90. PMC: 3308014. DOI: 10.1097/gme.0b013e31821f5d25. View

2.
Thurston R, Johnson B, Shufelt C, Braunstein G, Berga S, Stanczyk F . Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause. 2016; 24(2):126-132. PMC: 5266637. DOI: 10.1097/GME.0000000000000731. View

3.
Eldridge R, Wentzensen N, Pfeiffer R, Brinton L, Hartge P, Guillemette C . Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes Control. 2020; 31(4):309-320. PMC: 7472689. DOI: 10.1007/s10552-020-01280-6. View

4.
Gold E, Wells C, Rasor M . The Association of Inflammation with Premenstrual Symptoms. J Womens Health (Larchmt). 2016; 25(9):865-74. PMC: 5311461. DOI: 10.1089/jwh.2015.5529. View

5.
Lau D, Dhillon B, Yan H, Szmitko P, Verma S . Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5):H2031-41. DOI: 10.1152/ajpheart.01058.2004. View